TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01303562

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole grain oats and barley
Description: One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole grain oats and barley
Description: One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole grain oats and barley
Description: One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
Study: NCT03873480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Marcaine without Epinephrine prior to the start of surgery
Description: The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
Study: NCT00454636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2/day, intravenous (IV), every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2/day, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2/day, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2/day, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2/day, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2, oral, twice daily per 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2, oral, twice daily per 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2/day, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2/day, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, oral, twice daily for 2 weeks
Study: NCT04670432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutoside
Description: 500 mg film-coated tablet
Study: NCT03377400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: concurrent radiotherapy
Study: NCT02215694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dual probiotics
Description: 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2g of powder daily without probiotics
Study: NCT01376128

Intervention type: DRUG
Intervention: Paroxetine
Study: NCT04120194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu
Description: Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent
Description: Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
Study: NCT01235052

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positon Emission Tomography using 18F-FMISO
Description: We will introduce a pretherapy \[18F\]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. \[18F\]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe \[18F\]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
Study: NCT03916653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseous resection using piezoelectric device in surgical crown lengthening
Description: In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osseous resection using conventional rotary instruments in surgical crown lengthening
Description: For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
Study: NCT00113490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: motavizumab (MEDI-524)
Description: Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
Study: NCT00679848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RS2 (RESTORe Suturing System)
Description: Suturing in stomach
Study: NCT02706080

Intervention type: OTHER
Intervention: emergency
Study: NCT03903250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A-GPC
Description: Taken orally in liquid form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: Taken orally in liquid form
Study: NCT02533583

Intervention type: DEVICE
Intervention: pulse oximetry (PHILIPS intelliven MP5)
Description: all newborn monitor pulse oximetry in left hand

Intervention type: DEVICE
Intervention: pulse oximetry (PHILIPS intelliven MP5)
Description: all newborn monitor pulse oximetry in left hand
Study: NCT04137809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMBLE
Description: Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
Study: NCT04037514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol 15 mg/kg/6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
Study: NCT00113490

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: palivizumab 15 mg/kg
Description: Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
Study: NCT02577159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
Study: NCT00453570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Description: 0.5 mL, IM
Study: NCT03557918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria.
Study: NCT00453570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed
Description: 0.5 mL, IM
Study: NCT00809042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine and hydroxyurea
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea and magnesium chloride
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea,L-carnitine and magnesium chloride
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
Study: NCT02260557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching selexipag 200 μg tablets to be administered orally twice daily
Study: NCT04032197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Study: NCT02465437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B Open-Label Extension
Description: JBT-101 20mg bid on Days 1-364
Study: NCT03996668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thigh High Compression Stockings
Description: Thigh high compression stockings will be placed after induction of anesthesia and intubation.
Study: NCT01344239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning(LRIP)
Description: LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
Study: NCT03464084

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsules containing microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: melatonin
Description: 5 mg of melatonin per os.

Intervention type: OTHER
Group type: OTHER
Intervention: bright light
Description: room light will be bright

Intervention type: OTHER
Group type: OTHER
Intervention: bright light
Description: room light will be bright

Intervention type: OTHER
Group type: OTHER
Intervention: dim light
Description: room light will be dim
Study: NCT03336931

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular profiling and drug testing
Description: 1. Laboratory analysis including:~   A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy
Study: NCT00006029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin hydrochloride
Study: NCT02986763

Intervention type: BIOLOGICAL
Intervention: Questionnaire, blood, urine, hair and dust samplings

Intervention type: BIOLOGICAL
Intervention: Questionnaire, blood, urine, hair and dust samplings
Study: NCT03967249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS GHR-LRx
Description: Participants will receive IONIS GHR-LRx by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin Receptor Ligand (SRL)
Description: Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
Study: NCT00006029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT04612985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XACT Robotic System
Description: CT-guided Minimally Invasive Procedures e.g., Biopsies
Study: NCT03076996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support group
Description: Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~* Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~* Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed
Study: NCT02949882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult
Description: Containing at least 6,5\*10\^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Peach Drink (AH Basic)
Description: Commercially available dairy drink with peach flavour.
Study: NCT03153800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bronchial basal cells
Description: Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
Study: NCT01001520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Description: Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
Study: NCT03146338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-rich mineral water (Rozana)
Description: intakes of 1.5 L by day
Study: NCT00536510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laropiprant/niacin (MK0524A)
Description: Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization.
Study: NCT02033044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
Study: NCT00767221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 8 mg PL-56 once daily for six months
Study: NCT05929742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: early rehabilitation
Description: Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
Study: NCT00465686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)
Description: ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergonomic desk and chair (Q-Learn Desk)
Description: child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
Study: NCT01490281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water-based exercise
Description: Interventions will consist of aerobic, muscular strength and flexibility exercises in the water

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: land-based exercise intervention
Description: Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
Study: NCT00404274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets
Description: Casopitant will be available in the dose strength of 20,30 or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets
Description: Casopitant will be available in the dose strength of 20,30 or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets
Description: Casopitant will be available in the dose strength of 20,30 or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin oral tablets
Description: Warfarin will be available in the dose strength of 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin oral tablets
Description: Warfarin will be available in the dose strength of 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin oral tablets
Description: Warfarin will be available in the dose strength of 5 mg
Study: NCT03093454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Essential Oil
Description: Lavender essential oil will be applied topically and by inhalation to the lavender group.
Study: NCT01127542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.